[go: up one dir, main page]

WO2022079739A1 - Compositions à dose fixe de cabotégravir et de rilpivirine - Google Patents

Compositions à dose fixe de cabotégravir et de rilpivirine Download PDF

Info

Publication number
WO2022079739A1
WO2022079739A1 PCT/IN2021/050986 IN2021050986W WO2022079739A1 WO 2022079739 A1 WO2022079739 A1 WO 2022079739A1 IN 2021050986 W IN2021050986 W IN 2021050986W WO 2022079739 A1 WO2022079739 A1 WO 2022079739A1
Authority
WO
WIPO (PCT)
Prior art keywords
sodium
composition
fixed dose
acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2021/050986
Other languages
English (en)
Inventor
Pradeep Bhadauria
Alagumurugan Alagarswamy
Deepak Gaikwad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of WO2022079739A1 publication Critical patent/WO2022079739A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • the present invention relates to a pharmaceutical composition administered in a form of injection comprising fixed dose of two or more active ingredients, a process for preparing such pharmaceutical composition, and use of the said pharmaceutical composition for the prevention, treatment and prophylaxis of AIDS.
  • Human immunodeficiency virus infection and related diseases are a major public health problem worldwide.
  • Human immunodeficiency virus type 1 (HIV-1) encodes three enzymes which are required for viral replication: reverse transcriptase, protease, and integrase.
  • reverse transcriptase a enzyme which is required for viral replication
  • protease a enzyme which is required for viral replication
  • integrase a enzyme which is required for viral replication
  • drugs targeting reverse transcriptase and protease are in wide use and have shown effectiveness, particularly when employed in combination, toxicity and development of resistant strains have limited their usefulness (Palella, et al. N. Engl. J. Med. (1998) 338:853- 860; Richman, D. D. Nature (2001) 410:995-1001).
  • a goal of antiretroviral therapy is to achieve viral suppression in the HIV infected patient.
  • Treatment guidelines published by the United States Department of Health and Human Services provide that achievement of viral suppression requires the use of combination therapies, i.e., several drugs from at least two or more drug classes.
  • combination therapies i.e., several drugs from at least two or more drug classes.
  • a standard course of care for a patient infected with HIV is to treat them with a combination of two or more antiviral agents.
  • this treatment uses at least one antiretroviral agents targeting HIV reverse transcriptase (a “backbone”) and/or one or more agents active against one or more different HIV targets, such as an HIV protease inhibitor, an HIV non-nucleoside or non-nucleotide inhibitor of reverse transcriptase, an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV integrase inhibitor, an HIV non-catalytic site (or allosteric) integrase inhibitor, or a combination thereof.
  • HIV protease inhibitor an HIV non-nucleoside or non-nucleotide inhibitor of reverse transcriptase
  • an HIV nucleoside or nucleotide inhibitor of reverse transcriptase an HIV integrase inhibitor
  • an HIV non-catalytic site or allosteric integrase inhibitor
  • HIV infection requires lifelong treatment. This means that as HIV-infected individuals achieve life expectancies near those of persons without HIV, HIV-infected individuals are likewise starting to receive treatment for nonHIV, common conditions such as diabetes, cardiovascular disease, arthritis, osteoporosis, or other age-associated conditions and diseases.
  • HIV medications including both bictegravir and emtricitabine
  • patient compliance Because all HIV drugs must be taken as part of a combination regimen, there must be better ways to ensure patient compliance in taking medication as prescribed. If there are too many pills to swallow, at too many time intervals, then dosing becomes inconvenient and complicated, and patient compliance with the treatment regimen is less likely.
  • Long-acting injectable ART may provide some patients with a convenient and discreet approach to manage HIV infection.
  • W02006116764 discloses integrase strand transfer inhibitors (INSTI) useful in the treatment of HIV infection and AIDS.
  • INSTI integrase strand transfer inhibitors
  • One of the compounds disclosed is cabotegravir ((3 S, 1 laR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,l 1,1 la- hexahydro-6-hydr- oxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[l,2-d]pyrazine- 8 -carb oxami de)
  • a compound of formula (I) also referred to as compound (I)
  • W02006106103 discloses parenteral formulations of TMC 278 (known as Rilpivirine) to be administered intermittently at a time interval of at least one week, and may also be administered at longer time intervals such as several weeks, e.g. 2,
  • W02007082922 discloses parenteral formulations of TMC278 (known as Rilpivirine) to be administered intermittently at a time interval of at least one week, or in particular at a time interval mentioned for the treatment of HIV wherein the intervals may be shorter where the blood plasma levels of TMC278 are deemed too low, e.g. when these approach the minimum blood plasma level specified hereinafter. The intervals may be longer where the blood plasma levels of TMC278 are deemed too high
  • W02012140220 discloses freeze dried/ lyophilized nanosuspension composition of Rilpivirine and a steric stabilizer, a surfactant (e.g. a polymeric surfactant) or a polymer for administration either through intramuscular (IM) or subcutaneous (SC) injection.
  • a surfactant e.g. a polymeric surfactant
  • IM intramuscular
  • SC subcutaneous
  • US 20170027933 discloses parenteral pharmaceutical composition of compound of formula (I) (known as cabotegravir) and a surfactant system comprising polysorbate, polyethylene glycol, mannitol, and water, wherein the composition has mean particle size of 200 .mu.m or less.
  • US 20200147079 discloses method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, however, as per the regimen, there are two separate injections (or vials) as kit which need to be administered separately and requires specific task to health care givers and patients to administer “initial” and “maintenance” doses.
  • the said kit product has already been commercially approved at least in Canada in the name of “Cabenuva” which specifically requires maintenance of the product under low temperatures of 2 °C to 8 °C. It would be noted that while handling of such temperature sensitive products, extreme care needs to be taken within the complete supply chain from logistics perspective, and any possible faltering may lead to degradation of the product leading to serious stability issue of the fixed dose product.
  • the treatment regimen comprises a fixed dose composition of at least two anti-retroviral agents with therapeutically effective and long lasting dosing schedule which is easily administered.
  • the fixed dose combination formulations containing potent antiretroviral drugs proven to be useful in the prophylaxis and/ or treatment of HIV infection.
  • the said fixed dose composition of at least two anti-retroviral agents is desired to be convenient and easy to administer, as well as showing good physical stability and low degradant/ impurity levels.
  • An object of the present invention is to provide a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer.
  • Another object of the present invention is to provide a process of manufacturing fixed dose composition administered by injection comprising at least two antiretroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer.
  • antiretroviral agents in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients
  • Yet another object of the present invention is to provide a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer for the prophylaxis and/ or treatment of HIV infection.
  • anti-retroviral agents in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients
  • Still another object is to provide a method of alleviating or treating or prophylaxis HIV infection by administering a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer.
  • Still another object is to provide the use of fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer in the treatment and/ or prophylaxis of HIV infection.
  • anti-retroviral agents in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients
  • a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer.
  • a process of manufacturing fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer.
  • anti-retroviral agents in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients
  • a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer for the prophylaxis and/ or treatment of HIV infection.
  • anti-retroviral agents in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients
  • a method of alleviating or treating or prophylaxis HIV infection by administering a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer.
  • a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients
  • a use of fixed dose composition administered by injection comprising at least two antiretroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer in the treatment and/ or prophylaxis of HIV infection.
  • antiretroviral agents in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients
  • a fixed dose composition administered by injection comprising cabotegravir or their salts, solvates, esters or other forms and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients wherein the said composition is stable at room temperature.
  • a drug product package comprising a fixed dose composition administered by injection comprising cabotegravir or their salts, solvates, esters or other forms and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients filled in a unit-dose or multi-dose vial along with an injectable device comprising an auto-injector or a pre-filled syringe such as a dual chamber pre-filled syringe and the instructions for using such injectable device.
  • a drug product package comprising a fixed dose composition administered by injection comprising cabotegravir or their salts, solvates, esters or other forms and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients filled in an injectable device comprising an auto-injector or a pre-filled syringe such as a dual chamber pre-filled syringe and the instructions for using the same.
  • Rilpivirine or 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2- pyrimidinyl]-amino]-benzonitrile is a known NNRTI, which can be prepared as described in W003/016306.
  • Rilpivirine can be used in base form or, which is preferred, as a suitable pharmaceutically acceptable salt form, in particular as an acid addition salt form.
  • the pharmaceutically acceptable addition salts are meant to comprise the therapeutically active non-toxic salt forms.
  • the acid addition salt forms can be obtained by treating the base form with appropriate acids as inorganic acids, for example, hydrohalic acids, e.g.
  • hydrochloric hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxy-propanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2 -hydroxy- 1,2, 3- propanetricarboxylic, methanesulfonic, ethanesulfonic, benzene-sulfonic, 4- methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2- hydroxybenzoic and the like acids.
  • Preferred for use in the present invention are the hydrohalic acid salts, in particular the hydrochloride salt.
  • Rilpivirine occurs in stereoisomeric forms, more in particular as E- and Z-isomeric forms. Both isomers may be used in the combinations of the present invention. Whenever reference is made herein to Rilpivirine, the E- and the Z-form as well as any mixture of both forms are meant to be included.
  • Rilpivirine for use in the invention is the E-isomer, i.e. (E)-4- [[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]- benzonitrile (hereinafter called E-Rilpivirine).
  • E-Rilpivirine The Z-isomer of Rilpivirine, i.e.
  • (Z)- 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]- benzonitrile (hereinafter called compound Z-Rilpivirine) can also be used. It has relatively high potency against wild-type HIV-1 but is less active against single and double mutants in comparison to the E-isomer.
  • Table 1 shows the IC50 value in nM of the E and Z-isomer of Rilpivirine.
  • the inventors of the present invention have developed a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer which not only solves the difficulty in arriving at the fixed dose composition but also improves patient compliance, and comparatively simplifies the task of health care givers as well as provides a room-temperature stable product which prominently differentiates from any existing therapies known for the prophylaxis and/ or treatment of HIV infection.
  • a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer.
  • the fixed dose composition according to this aspect of the present invention comprise an effective amount of cabotegravir and rilpivirine or their respective pharmaceutically acceptable salt, solvates, esters or other forms thereof, and one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer.
  • the fixed dose composition may be provided in multi-dose vials or with a suitable prefilled syringe (PFS) device or an auto-injector for e.g. dual chamber syringe device associated with the said fixed dose composition comprising a therapeutically effective amount of amount of cabotegravir and rilpivirine or their respective pharmaceutically acceptable salt, solvates, esters or other forms thereof, and one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer as a drug product package.
  • PFS prefilled syringe
  • the room-temperature stability of the fixed dose composition substantially depends on the specific composition of the polymers used, and the mean particle size of the composition ranging from 0.1-1.0pm, more specifically about 0.1 pm to about 0.3 pm.
  • the fixed dose composition allows administration of high doses of both cabotegravir and rilpivirine which significantly uptakes the existing therapy from an acceptance perspective thereby leading to success of therapeutic regimen.
  • the terms “comprise(s)” and “comprising” are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases “having at least” or “including at least”.
  • the term “comprising” means that the process includes at least the recited steps, but may include additional steps.
  • the term “comprising” means that the compound or composition includes at least the recited features or components, but may also include additional features or components.
  • Suitable pharmaceutically acceptable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable esters, pharmaceutically acceptable isomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc.
  • treating refers to relieving, reducing or alleviating at least one symptom in a subject or effecting a delay of progression of a disease.
  • treatment can be the diminishment of one or several symptoms of a disorder or complete eradication of a disorder, such as cancer.
  • the term “treat” also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease.
  • prophylaxis refers to treatment for a subject who, while not being infected by HIV , is in a situation wherein they are susceptible to or subject to the possibility of acquiring the disease.
  • pharmaceutically acceptable salt refers to a charged species of the parent compound and its counter ion, which is typically used to modify the solubility characteristics of the parent compound and/or to reduce any significant irritation to an organism by the parent compound, while not abrogating the biological activity and properties of the administered compound.
  • pharmaceutically acceptable salts include salts comprising an anion such as a carboxylate or sulfate anion, and/or a cation such as, but not limited to, ammonium, sodium, potassium, and the like. Suitable salts are described in, e.g., Birge et ai. [J Pharma Sci 1977, 66: 1-19],
  • fixed dose composition refers to a formulation of cabotegravir and rilpivirine described herein with other chemical components such as pharmaceutically acceptable carriers and excipients as a single composition, or alternatively, two separate formulations each of cabotegravir and rilpivirine with their respective chemical components such as pharmaceutically acceptable carriers and excipients configured in a suitable injectable device for simultaneous or concomitant administration.
  • pharmaceutically acceptable carrier refers to a carrier, adjuvant, or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
  • excipient(s) refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include surfactants, lyoprotectants, isotonicity agents, pH adjusters, buffers, preservatives, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
  • a room temperature stable fixed dose composition administered by injection comprising cabotegravir and rilpivirine along with one or more pharmaceutically acceptable excipients.
  • the fixed dose composition comprising cabotegravir and rilpivirine along with one or more pharmaceutically acceptable excipients is meant to be administered once every 4 weeks or once every 8 weeks or longer.
  • the fixed dose composition there may be provided a drug product package comprising a fixed dose composition administered by injection comprising cabotegravir or their salts, solvates, esters or other forms and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients filled in a unit-dose or multidose vial along with an injectable device comprising an auto-injector or a pre-filled syringe such as a dual chamber pre-filled syringe and the instructions for using such injectable device.
  • an injectable device comprising an auto-injector or a pre-filled syringe such as a dual chamber pre-filled syringe and the instructions for using such injectable device.
  • a drug product package comprising a fixed dose composition administered by injection comprising cabotegravir or their salts, solvates, esters or other forms and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients filled in an injectable device comprising an auto-injector or a pre-filled syringe such as a dual chamber pre-filled syringe and the instructions for using the same.
  • the fixed dose composition may be presented in the form of liquid solution/ suspension or as powder for solution/ suspension or as liposomal formulation comprising a therapeutically effective amount of cabotegravir or their salts, solvates, esters or other forms and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients for injectable administration through a suitable injectable device as a single composition.
  • the liquid solution/ suspension or as powder for solution/ suspension or as liposomal formulation may be packed in a unit dose or multidose vial or in an injectable device as a single composition as referred within the specification.
  • the fixed dose composition may be presented with individual formulations each comprising a therapeutically effective amount of cabotegravir or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients for injectable administration and a therapeutically effective amount of rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients for injectable administration.
  • the scope of the present invention may envisage same presentation or different presentation of cabotegravir formulation and rilpivirine formulation respectively i.e.
  • a fixed dose composition may either comprise a liquid solution of cabotegravir formulation and a liquid solution of rilpivirine formulation or, may comprise a liquid suspension of cabotegravir formulation and a liquid solution of rilpivirine formulation, or may comprise a liquid solution of cabotegravir formulation and a liquid suspension of rilpivirine formulation, or a powder for solution/ suspension of cabotegravir formulation and a powder for solution/ suspension of rilpivirine formulation, or liposomal presentation each of cabotegravir formulation and rilpivirine formulation, and other possible combinations may be envisaged under the scope of the present invention.
  • the fixed dose composition may comprise from about 400 mg/ vial to about 600 mg/ vial of Cabotegravir (with an equivalent concentration of 100 mg/ml to 300 mg/ml) and from about 600 mg/ vial to about 900 mg/ vial of Rilpivirine (with an equivalent concentration of 100 mg/ml to 450 mg/ml) of the total weight of the composition and the volume of the fixed dose composition is about 2 ml to about 10 ml, preferably about 3 ml to about 7 ml.
  • the fixed dose composition of the present invention may comprise cabotegravir and rilpivirine in micronized form or as a slurry.
  • Suitable micronization techniques like microfluidizer, high pressure homogenizer, ball mill, sonication and other such techniques commonly known in the art can be employed to effectively size reduce the average particle size of cabotegravir and rilpivirine thereof.
  • the average particle size of both cabotegravir and rilpivirine desired for effective usage of the compositions of the present invention can range from about 0.1 pm to about 5.0 pm.
  • the average particle size of the fixed dose composition plays an important role, and the desired average particle size range of the fixed dose composition may range from 0.1 pm to 0.5 pm.
  • the fixed dose composition of the present invention may have a pH range of about 3 to about 8.
  • the pH may be adjusted by the addition of one or more pharmaceutically acceptable acids.
  • suitable pharmaceutically acceptable acids include inorganic acids, such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, and phosphoric acid, and combinations thereof.
  • suitable pharmacologically acceptable acids include organic acids, such as ascorbic acid, citric acid, malic acid, maleic acid, tartaric acid, succinic acid, fumaric acid, acetic acid, formic acid, and/or propionic acid or other than acid variants which comprises sodium hydroxide.
  • the pH is maintained using combination of buffering agents and/ or pH adjusting agent.
  • the pH is maintained using pharmaceutically acceptable buffers comprising organic or inorganic buffering agents such as citrate, acetate, ascorbate acid, succinate, maleate, borate and phosphate, fumaric acid and citric acid.
  • Suitable tonicity adjusting agents may include, but are not limited to, ammonium carbonate, ammonium chloride, ammonium lactate, ammonium nitrate, ammonium phosphate, ammonium sulfate, ascorbic acid, bismuth sodium tartrate, boric acid, calcium chloride, calcium disodium edetate, calcium gluconate, calcium lactate, citric acid, dextrose, diethanolamine, dimethyl sulfoxide, edetate disodium, edetate trisodium monohydrate, fluorescein sodium, glucose anhydrous/ monohydrate, fructose, galactose, glycerin, lactic acid, lactose, magnesium chloride, magnesium sulfate, mannitol
  • the tonicity adjusting agent in the fixed dose composition of the present invention may range from 10.0 % to 20.0% w/w of the total composition e.g. glucose monohydrate.
  • Suitable lyoprotectants that may be used under the present context for the fixed dose composition include, but are not limited to, natural lyoprotectants which includes sugars such as sucrose, glucose monohydrate/ anhydrous or trehalose, or other lyoprotectants like an amino acid, such as monosodium glutamate, non-crystalline glycine or histidine; a methylamine such, as betaine; a lyotropic salt, such as magnesium sulfate; a polyol, such as trihydric or higher sugar alcohols, e.g., glycerin, erythritol, glycerol, arabitol, xylitol, sorbitol, and mannitol; propylene glycol; polyvinylpyrrolidones (e.g.,
  • the lyoprotectants in the fixed dose composition of the present invention may range from about 1% w/w to about 20% w/w of the total composition e.g. PVP.
  • Suitable surfactants that may be used under the present context for the fixed dose composition as suspending/ wetting agents include, but are not limited to, nonionic surfactants, such as polysorbates (e.g., polysorbate 80 or polysorbate 20); sorbitan fatty acid ester (Span 20 or 80); Poloxamers (e.g., Poloxamer 188, Poloxamer 338); Polyoxyl castor oil (e.g., Cremophor EL); Polyoxyl hydrogenated castor oil (e.g., Cremophor RH 40); TritonTM (e.#., TritonTMX-100).
  • nonionic surfactants such as polysorbates (e.g., polysorbate 80 or polysorbate 20); sorbitan fatty acid ester (Span 20 or 80); Poloxamers (e.g., Poloxamer 188, Poloxamer 338); Polyoxyl castor oil (e.g., Cremophor EL); Polyoxyl hydrogenated castor oil
  • surfactants include but are not limited to, Myristyl-gamma-picolinium chloride (MGP), sodium dodecyl sulfate (SDS); sodium octyl glycoside; lauryl-sulfobetaine; myristyl-sulfobetaine; linoleyl-sulfobetaine; stearyl-sulfobetaine; lauryl-sarcosine; myristyl-sarcosine; linoleyl-sarcosine; stearyl-sarcosine; linoleyl-betaine; myristyl-betaine; cetylbetaine; lauroamidopropyl-betaine; cocamidopropyl -betaine; linoleamidopropyl- betaine; myristamidopropyl-betaine, palmidopropyl-betaine; isostearamidopropyl- betaine (e.
  • any solvent/ cosolvent that is suitable for injectables and capable of dissolving or dispersing cabotegravir and/ or rilpivirine in the mixture of cosolvent and water can be used, or merely, water may be used as the vehicle without any solvents/ cosolvents.
  • suitable cosolvents include, for example, alcohols, ethers, hydrocarbons, and perfluorocarbons.
  • the cosolvent is a short chain polar alcohol. More preferably, the cosolvent is an aliphatic alcohol having from one to six carbon atoms, such as ethanol or isopropanol. The most preferred cosolvent is ethanol.
  • suitable hydrocarbons include n-butane, isobutane, pentane, neopentane and isopentanes.
  • suitable ethers include dimethyl ether and diethyl ether.
  • suitable perfluorocarbons include perfluoropropane, perfluorobutane, perfluorocyclobutane, and perfluoropentane.
  • the cosolvents in the fixed dose composition of the present invention may range from about 5% w/w to about 50% w/w of the total composition.
  • Suitable antioxidants include, but are not limited to, ascorbic acid, monothioglycerol, L-Cysteine, L-Methionine, sodium meta bisuifite, sodium thiosulfate, Butylated hydroxyanisole, Butylated hydroxytoluene, Alpha Tocopherol etc.
  • phospholipids such as egg yolk phosphatidylcholide, hydrogenated soybean phosphatidylcholide, dimyristoyphosphatidylcholide, diolyeolyl-dipalmitoyleolylphosphatidylcholide and dipalmitoyl phosphatidylcholide (DPPC) present in an amount ranging from about 0.05% w/v to about 5.0% w/v of the total composition.
  • phospholipids such as egg yolk phosphatidylcholide, hydrogenated soybean phosphatidylcholide, dimyristoyphosphatidylcholide, diolyeolyl-dipalmitoyleolylphosphatidylcholide and dipalmitoyl phosphatidylcholide (DPPC) present in an amount ranging from about 0.05% w/v to about 5.0% w/v of the total composition.
  • DPPC dipalmitoyl phosphatidylcholide
  • the fixed dose composition that is presented with individual formulations each comprising a therapeutically effective amount of cabotegravir or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients for injectable administration and a therapeutically effective amount of rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients for injectable administration may be administered for prevention and/ or treatment comprising administration every 4 weeks or one month, more particularly the treatment is every 4 weeks.
  • the dose is 400 mg cabotegravir and 600 mg rilpivirine, administered every four weeks.
  • the 400 mg cabotegravir and 600 mg rilpivirine are administered separately in two 2-mL injections, every four weeks.
  • the dosing regimen may involve stabilizing the patient with oral therapy for one month with both the respective drugs, followed by loading dose of extended release injections of 600mg cabotegravir (3mL) and 900mg rilpivirine (3mL) as two separate injections for the second month, and later, a maintenance dose of Extended release injections of 400mg cabotegravir (2mL) and 600mg rilpivirine (2mL) as two separate injections for the third month.
  • the fixed dose composition that is presented with individual formulations each comprising a therapeutically effective amount of cabotegravir or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients for injectable administration and a therapeutically effective amount of rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients for injectable administration may be administered for prevention and/ or treatment comprising administration every 8 weeks or 2 months, more particularly the treatment is every 8 weeks.
  • the dose is 600 mg cabotegravir and 900 mg rilpivirine, administered every eight weeks.
  • the 600 mg cabotegravir and 900 mg rilpivirine are administered separately in two 3-mL injections, every 8 weeks.
  • the fixed dose composition that is presented as a single composition comprising a therapeutically effective amount of cabotegravir or their salts, solvates, esters or other forms and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients for injectable administration may be administered for prevention and/ or treatment comprising administration every 4 weeks or 8 weeks.
  • the dose is 600 mg cabotegravir and 900 mg rilpivirine, or 400 mg cabotegravir and 600 mg rilpivirine administered every four weeks as a single injection.
  • dose is 600 mg cabotegravir and 900 mg rilpivirine, or 400 mg cabotegravir and 600 mg rilpivirine administered every four weeks are administered separately in two separate injections, every four weeks.
  • a process of preparing a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer.
  • the composition according to the present invention may be manufactured by conventional techniques known to person skilled in the art to arrive at either liquid solution/ suspension, powder for solution/ suspension or a liposomal formulation.
  • a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer for the prophylaxis and/ or treatment of HIV infection.
  • anti-retroviral agents in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients
  • a method of alleviating or treating or prophylaxis HIV infection by administering a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer.
  • a fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients
  • a use of fixed dose composition administered by injection comprising at least two anti-retroviral agents, in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer in the treatment and/ or prophylaxis of HIV infection.
  • anti-retroviral agents in particular, cabotegravir and rilpivirine or their salts, solvates, esters or other forms
  • one or more pharmaceutically acceptable excipients by administering once every 4 weeks or once every 8 weeks or longer in the treatment and/ or prophylaxis of HIV infection.
  • a fixed dose composition administered by injection comprising cabotegravir or their salts, solvates, esters or other forms and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients wherein the said composition is stable at room temperature.
  • a drug product package comprising a fixed dose composition administered by injection comprising cabotegravir or their salts, solvates, esters or other forms and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients filled in a unit-dose or multi-dose vial along with an injectable device comprising an auto-injector or a pre-filled syringe such as a dual chamber pre-filled syringe and the instructions for using such injectable device.
  • a drug product package comprising a fixed dose composition administered by injection comprising cabotegravir or their salts, solvates, esters or other forms and rilpivirine or their salts, solvates, esters or other forms along with one or more pharmaceutically acceptable excipients filled in an injectable device comprising an auto-injector or a pre-filled syringe such as a dual chamber pre-filled syringe and the instructions for using the same.
  • the fixed dose composition comprising Cabotegravir and Rilpivirine may require specific dosage amounts and specific frequency of administrations specifically considering their individual established doses, the dosing frequency, patient adherence and the regimen adopted.
  • the dosage and administration of the combination composition may require specific dosage amounts and specific frequency of administrations specifically considering their individual established doses, the dosing frequency, patient adherence and the regimen adopted.
  • the following preparative and testing methods and examples are set forth. The following examples are for the purpose of illustration of the invention only and are not intended in any way to limit the scope of the present invention.
  • Formulation I Cabotegravir + Rilpivirine fixed dose combination (Single Injection) - Liquid suspension / Lyophilized product
  • Lico protectants such as PVP K-17, K-30 or Sucrose may be added to minimize particle aggregation during lyophilization process.
  • the product can be filled in a suitable ampule, vial or prefilled syringes and supplied as a Liquid suspension product.
  • the suspension can be lyophilized further.
  • the lyophilized product appropriate reconstitution using 3 - 6 ml of Water for Injection before administration.
  • vials also may be terminally sterilized using gamma or e-beam radiation of finished product instead of aseptic processing.
  • Injection - Liquid suspension/ Lyophilized product minimize particle aggregation during lyophilization process.
  • suspending agents such as PEG 3350 or carboxymethyl cellulose sodium, surfactants such as Polysorbate 20 and/ or Span 20 sequentially while mixing gently using a mixer/ overhead stirrer.
  • the product can be filled in a suitable ampule, vial or prefilled syringes and supplied as a Liquid suspension product.
  • the suspension can be lyophilized further.
  • the lyophilized product appropriate reconstitution using 3 - 6 ml of Water for Injection before administration.
  • vials also may be terminally sterilized using gamma or e-beam radiation of finished product instead of aseptic processing.
  • the lyophilized formulations (mentioned in the Formulation I and II above) can be filled in a dual chamber prefilled syringe along with the diluents (lyophilized cake in first chamber and diluent filled in second chamber) to be administered directly to the patient.
  • the dual chamber pre-filled syringe will have a room temperature storage conditions.
  • Manufacturing process i. Collect required amount of Water for Injection (about 20 - 30% batch volume) in suitable manufacturing vessel. ii. Add and dissolve Poloxamer 388, using mixer or overhead stirrer under gentle mixing. iii. Add and suspend required amount of Cabotegravir using mixer or overhead stirrer. iv. Make up the volume of drug slurry with Water for Injection to get the required strength of drug slurry (about 50% of batch volume). v. Subject the drug slurry for particle size reduction in nano-mill instrument or ball milling instrument. . Preparation of excipient phase
  • Manufacturing process i. Collect required amount of WFI (about 30% batch volume) in suitable manufacturing vessel and warm it upto 40°C. ii. Add and dissolve citric acid anhydrous, glucose monohydrate and PVP K-17 in sequential manner under gentle mixing to obtain a clear solution. iii. Adjust the pH, if required using diluted hydrochloric acid or sodium hydroxide solution to about pH 6 to 7. iv. Make up the volume (to about 50% of batch volume) using water for Injection under mixing. v. Check clarity and perform the filtration using 0.22 pm PVDF membrane
  • Manufacturing process i. Mix the excipient phase into the drug slurry in 1 : 1 ratio to obtain the final liquid drug suspension having 100 mg to 200 mg of Cabotegravir concentration.
  • the product can be filled dual chamber prefilled syringes (2 mL to 4 mL filled in in either chamber 1 or 2) and supplied as a Liquid suspension product.
  • lyophilized product i. Fill the drug suspension (2 mL to 4 mL) in suitable vials (preferably 6R vials) or in a dual chamber syringe and lyophilized to remove the water with appropriate selection and control of freezing, sublimation and secondary drying parameters.
  • suitable vials preferably 6R vials
  • the lyophilized product appropriate reconstitution using 3 - 6 ml of Water for Injection before administration.
  • vials also may be terminally sterilized using gamma or e-beam radiation of finished product instead of aseptic processing.
  • Manufacturing process i. Collect required amount of Water for Injection (about 45% batch volume) in suitable manufacturing vessel. ii. Add and dissolve Poloxamer 388, using mixer or overhead stirrer under gentle mixing. iii. Add and suspend required amount of Rilpivirine using mixer or overhead stirrer. iv. Make up the volume of drug slurry with Water for Injection to get the required strength of drug slurry (about 75% of batch volume). v. Subject the drug slurry for particle size reduction in nano-mill instrument or ball milling instrument.
  • Manufacturing process i. Mix the excipient phase into the drug slurry in 1 :3 ratio to obtain the final liquid drug suspension having 150 mg to 300 mg of Rilpivirine concentration.
  • the product can be filled dual chamber prefilled syringes (3 mL to 6 mL filled in in either chamber 1 or 2) and supplied as a Liquid suspension product.
  • lyophilized product i. Fill the drug suspension (4 mL to 6 mL) in suitable vials (preferably 10R vials) or in a dual chamber syringe and lyophilized to remove the water with appropriate selection and control of freezing, sublimation and secondary drying parameters.
  • the lyophilized product appropriate reconstitution using 3 - 6 ml of Water for Injection before administration.
  • PVPK-12 PVP K-17
  • Trehalose Sorbitol
  • Sucrose Glucose Monohydrate
  • Mannitol
  • Lyophilized product suitable for room temperature storage can be prepared by freeze drying the vials on lyophilization chamber to remove the water with appropriate selection and control of freezing, sublimation and secondary drying parameters.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique administrée sous la forme d'une injection comprenant une dose fixe d'au moins deux principes actifs, à savoir le cabotégravir et la rilpivirine et éventuellement d'autres principes actifs, ainsi qu'un procédé de préparation de ladite composition pharmaceutique. L'invention concerne également l'utilisation d'une telle composition pharmaceutique à dose fixe pour la prévention, le traitement et la prophylaxie du SIDA.
PCT/IN2021/050986 2020-10-14 2021-10-14 Compositions à dose fixe de cabotégravir et de rilpivirine Ceased WO2022079739A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021044747 2020-10-14
IN202021044747 2020-10-14

Publications (1)

Publication Number Publication Date
WO2022079739A1 true WO2022079739A1 (fr) 2022-04-21

Family

ID=78617454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/050986 Ceased WO2022079739A1 (fr) 2020-10-14 2021-10-14 Compositions à dose fixe de cabotégravir et de rilpivirine

Country Status (1)

Country Link
WO (1) WO2022079739A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115844838A (zh) * 2022-12-01 2023-03-28 浙江萃泽医药科技有限公司 一种可注射的药物组合物及其制备方法与应用
WO2025068912A1 (fr) * 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Compositions pharmaceutiques

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016306A1 (fr) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Derives de pyrimidines inhibiteurs de vih
WO2006088173A1 (fr) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Dérivé de carbamoylpyridone bicyclique ayant une activité d'inhibition de la vih intégrase
WO2006106103A2 (fr) 2005-04-04 2006-10-12 Tibotec Pharmaceuticals Ltd. Prévention d'infection par le vih
WO2006116764A1 (fr) 2005-04-28 2006-11-02 Smithkline Beecham Corporation Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih
WO2007082922A2 (fr) 2006-01-20 2007-07-26 Tibotec Pharmaceuticals Ltd. Traitement a long terme de l'infection par le vih
WO2012140220A1 (fr) 2011-04-15 2012-10-18 Janssen Pharmaceutica Nv Nanosuspensions de médicament lyophilisées
US20170027933A1 (en) 2010-09-16 2017-02-02 Viiv Healthcare Company Pharmaceutical Compositions
US20200147079A1 (en) 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016306A1 (fr) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Derives de pyrimidines inhibiteurs de vih
WO2006088173A1 (fr) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Dérivé de carbamoylpyridone bicyclique ayant une activité d'inhibition de la vih intégrase
WO2006106103A2 (fr) 2005-04-04 2006-10-12 Tibotec Pharmaceuticals Ltd. Prévention d'infection par le vih
WO2006116764A1 (fr) 2005-04-28 2006-11-02 Smithkline Beecham Corporation Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih
WO2007082922A2 (fr) 2006-01-20 2007-07-26 Tibotec Pharmaceuticals Ltd. Traitement a long terme de l'infection par le vih
US20170027933A1 (en) 2010-09-16 2017-02-02 Viiv Healthcare Company Pharmaceutical Compositions
WO2012140220A1 (fr) 2011-04-15 2012-10-18 Janssen Pharmaceutica Nv Nanosuspensions de médicament lyophilisées
US20200147079A1 (en) 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BIRGE, J PHARMA SCI, vol. 66, 1977, pages 1 - 19
MARGOLIS D A ET AL: "Long-acting antiviral agents for HIV treatment", CURRENT OPINION IN HIV AND AIDS, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 10, no. 4, 1 July 2015 (2015-07-01), pages 246 - 252, XP009508264, ISSN: 1746-630X, DOI: 10.1097/COH.0000000000000169 *
MARGOLIS D ABOFFITO M: "Long-acting antiviral agents for HIV treatment", CURR OPIN HIV AIDS, vol. 10, no. 4, 2015, pages 246 - 52, XP009508264, DOI: 10.1097/COH.0000000000000169
PALELLA ET AL., N. ENGL. J. MED., vol. 338, 1998, pages 853 - 860
PANEL: "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents", 14 March 2014, DEPARTMENT OF HEALTH AND HUMAN SERVICES, article "Antiretroviral Guidelines for Adults and Adolescents"
RICHMAN, D. D., NATURE, vol. 410, 2001, pages 995 - 1001
SURVE DHANASHREE H ET AL: "Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 324, 24 May 2020 (2020-05-24), pages 379 - 404, XP086244565, ISSN: 0168-3659, [retrieved on 20200524], DOI: 10.1016/J.JCONREL.2020.05.022 *
ZHOU ET AL., AIDS PATIENT CARE AND STDS, vol. 28, no. 6, pages 311 - 317
ZHOU ET AL.: "AIDS PATIENT CARE and STDs", TOTAL DAILY PILL BURDEN IN HIV-INFECTED PATIENTS IN THE SOUTHERN, vol. 28, no. 6, 2014, pages 311 - 317

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115844838A (zh) * 2022-12-01 2023-03-28 浙江萃泽医药科技有限公司 一种可注射的药物组合物及其制备方法与应用
CN115844838B (zh) * 2022-12-01 2023-10-24 浙江萃泽医药科技有限公司 一种可注射的药物组合物
WO2024113533A1 (fr) * 2022-12-01 2024-06-06 浙江萃泽医药科技有限公司 Composition pharmaceutique injectable, procédé de préparation associé et son utilisation
WO2025068912A1 (fr) * 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Compositions pharmaceutiques

Similar Documents

Publication Publication Date Title
US20240307387A1 (en) Pharmaceutical compositions
AU2013358897B2 (en) Pharmaceutical compositions
US10092523B2 (en) Long acting pharmaceutical compositions
WO2022079739A1 (fr) Compositions à dose fixe de cabotégravir et de rilpivirine
US20150209273A1 (en) Pharmaceutical Compositions
WO2016036588A1 (fr) Suspensions pharmaceutiques contenant de l'étoricoxib
US11077050B2 (en) Formulation for parenteral administration
JP2023550079A (ja) Ｈｉｖ感染症の治療又は予防

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21806833

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21806833

Country of ref document: EP

Kind code of ref document: A1